(All committee members underwent the same ethics review and vetting process required of all FDA advisory committee members, Emily Hilliard, a spokesperson for the Department of Health and Human Services, told me in an email.) The decision is only a recommendation, and the FDA would still need to sign off on an actual rule change
Norepinephrine transporter impairment is linked to depression, panic disorder, tachycardia, and POTS.[ref] Rare mutations in the SLC6A2 gene have been strongly linked to POTS, and a more common variant increases susceptibility a little bit
Body weight considerations Unlike some peptides where dosing scales with body weight, cagrilintide uses fixed doses across weight categories in clinical trials
hypoglycemia tracks the insulin background not tirzepatide dose (SURPASS-5): Dahl JAMA 2022
Start at 200 mcg daily and increase gradually over 2-3 weeks